Pharma BD Deal Intelligence
Alexion announced acquisition of New York-based Syntimmune in September 2018 for $400M upfront plus up to $800M in milestones tied to eight ALXN1830 development goals (total $1.2B); the deal closed November 2018. The asset was SYNT001 (renamed ALXN1830), a first-in-class anti-FcRn monoclonal antibody for warm autoimmune hemolytic anemia and pemphigus. After AstraZeneca acquired Alexion in 2021, a portfolio review scrapped ALXN1830 in December 2021, triggering breach-of-contract litigation by Syntimmune's former stockholders (via Shareholder Representative Services). The Delaware Court of Chancery found for the stockholders in two post-trial rulings: a September 5, 2024 decision holding Alexion breached its commercially-reasonable-efforts (CRE) obligation and awarding $130M on the first unpaid milestone, and a June 11, 2025 damages decision awarding an additional $180.94M in expectation damages (the probability-weighted value of the forgone earnouts at the time of breach). Combined liability is roughly $310M before interest; with pre- and post-judgment interest the June 2025 award alone is expected to total ~$220M. The court found Alexion's termination was driven by ~$500M in promised AstraZeneca merger synergies rather than a good-faith development assessment. No FcRn asset ultimately reached market for Alexion; argenx's efgartigimod (2021) and others later defined the FcRn category. The case stands as a leading Delaware precedent on CRE earnout obligations in pharma M&A.
Assessment window: 5yr post-close.